Clinical trials: Acute Adult T-Cell Leukemia/Lymphoma
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
B-Cell Acute Lymphoblastic Leukemia, Adult
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
The purpose of this clinical trial is to learn if autologous bedside CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults.
- Trial name
- NCT07277504
- Testing
- CD19 CAR T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The General Hospital of Western Theater Command
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT04620655
- Testing
- RD13-01 cell infusion
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Min Xiang
Leukemia, Myelodysplastic Syndromes
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
RATIONALE: Monoclonal antibodies can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00618696
- Testing
- anti-CD45 monoclonal antibody AHN-12, yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma
- Trial name
- NCT04934774
- Testing
- CD7 CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL
This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in adults with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.
- Trial name
- NCT04888442
- Testing
- pCAR-19B cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities.
- Conditions
- B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- NCT04214886
- Testing
- Fludarabine, Cyclophosphamide, CD19-CD34 CAR transduced T cells
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Loyola University
Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL.
- Trial name
- NCT06481228
- Testing
- CAR-T cells, Venetoclax, Olverembatinib
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT00720109
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Acute T Lymphpblastic Leukemia/Lymphoma
VHAG in Treating R/R T-ALL/LBL
Acute T cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive type of leukemia that results from the malignant evolution of T-lineage progenitor cells at different differentiation stages.
- Trial name
- NCT06742463
- Testing
- Venetoclax, homoharringtonine, Cytarabine (Ara-C)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this research study is to determine the acceptable upper limit dose of nivolumab in combination with dasatinib that may be given to patients with relapsed/refractory philadelphia chromosome positive acute…
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT02819804
- Testing
- Dasatinib, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Cancer
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00357084
- Testing
- methotrexate, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL
- Trial name
- Phase I/II (NCT06874946)
- Testing
- CD5-targeted CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital